CMS rejects Iowa’s plan to direct more Medicaid funds to private nursing homes

Iowa’s “supplemental payment plan” for nursing homes was rejected by CMS over the legality of county hospitals assuming the licenses of for-profit nursing homes in order to qualify for an estimated $1 billion in additional Medicaid payments.

According to the Des Moines Register, this is third attempt Iowa has attempted to gain approval for a version of this plan. It was first formalized in 2016 when state lawmakers passed the change into law—with the legislation being written entirely by lobbyists for the nursing home industry.

After giving the privately-owned, for-profit nursing homes the appearance of a hospital affiliation, the facilities would then kick back a share of the additional Medicaid payments to the state. CMS would therefore spending an additional $200 million annually matching a state Medicaid investment that doesn’t exist.

Even though this version of the proposal restricted the new funding for quality of care improvements, CMS said it still violated federal standards on how states can finance their share of Medicaid funds.

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.